FDA Hypocrisy: Drug Trials, Black Box Warnings & Oversight
This paper critically examines the Food and Drug Administration's (FDA) problematic inconsistencies in regulating food, drugs, and medical devices. Drawing on peer-reviewed literature, it explores how the FDA has selectively altered or withheld manufacturer-submitted data from public and professional view, raising serious concerns about transparency and institutional integrity. The paper addresses the misapplication of Metformin for non-diabetic dementia patients, the dangers of expedited drug approval processes under political pressure, and the significance of Black box warnings. It also considers the broader implications of speedy approvals for public health, including post-market safety issues and the economic burden of drug withdrawals.
- Introduction: The FDA's Moral Accountability: FDA's integrity questioned amid political and pharmaceutical pressures
- Clinical Trial Evidence and Inconsistencies: Metformin trials reveal limits of cross-population drug generalization
- FDA Data Manipulation and Selective Reporting: Published FDA data differs from manufacturer-submitted findings
- Black Box Warnings and Expedited Drug Approvals: Faster approvals increase psychiatric and cardiovascular drug risks
- Public Health Consequences of Accelerated Approvals: Market withdrawals and economic costs follow inadequate drug testing
- Conclusion: The Case for Reform and Vigilance: Proactive surveillance and Black box warnings needed post-approval
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- Uses specific, named case studies (Metformin, Bextra, Zelnorm, Covid-19 vaccines) to ground abstract regulatory critiques in concrete evidence.
- Draws on a diverse range of peer-reviewed sources to support each claim, lending credibility to an argumentative stance that could otherwise appear polemical.
- Balances institutional critique with acknowledgment of genuine public health complexity, such as pandemic-era vaccine urgency versus long-term safety testing requirements.
Key academic technique demonstrated
The paper employs evidence-based argumentation by systematically pairing each regulatory critique with corresponding citations from clinical and policy literature. Rather than relying solely on opinion, the author references systematic reviews, cross-sectional comparisons, and government publications to substantiate claims about FDA data manipulation, selective reporting, and expedited approval risks.
Structure breakdown
The paper opens with a broad thesis questioning FDA accountability and then narrows into specific domains: clinical trial integrity, data reporting discrepancies, Black box warning policies, and accelerated approvals. Each section builds on the last, moving from evidence-level concerns to systemic and economic consequences. The conclusion calls for proactive surveillance and reform. This funnel structure — broad claim → specific evidence → systemic implication — is typical of policy-critique essays at the undergraduate or graduate level.
Introduction: The FDA's Moral Accountability
How can one trust a daily supplement, hormone replacement, or pharmaceutical intervention when political or pharmaceutical agendas may influence its approval? There is a pressing need for the Food and Drug Administration (FDA) to realign its moral objectivity. The agency has held American population health and wellbeing in its hands since its inception, yet it increasingly uses media and patient-provider channels for public relations purposes rather than genuine transparency. It has become apparent that clinical trials, responses to adverse prescription reactions, and endorsements of non-regulated foods and medications have been conducted in service of special interests and monetary gains backed by large businesses and pharmaceutical companies.
This paper reviews previous literature regarding the FDA's problematic inconsistencies, its oversight of subsidiaries, authorization processes, and the implementation of food and drug policies. Additional areas of focus include Black box warning indications, the expediting of drug trials, and the FDA's exercise of power over what data — submitted to the agency by manufacturers for approval — is actually disclosed to the public.
Create your account
Always verify citation format against your institution’s current style guide requirements.